Sep 10, 2025 08:01AM
Sep 10, 2025 08:00AM
Jul 8, 2025 08:01AM
Jul 8, 2025 08:00AM
May 14, 2025 09:00AM
Apr 15, 2025 08:35AM
Apr 15, 2025 08:30AM Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Mar 27, 2025 08:01AM
Mar 27, 2025 08:00AM
Mar 17, 2025 04:16PM
Mar 4, 2025 08:03AM
Feb 25, 2025 07:59AM
Feb 25, 2025 07:58AM
Jan 29, 2025 04:05PM Dermata to Present on BioPub on January 31, 2025
Jan 21, 2025 08:03AM
Jan 21, 2025 08:00AM
Dec 16, 2024 09:00AM
Dec 10, 2024 09:08AM
Dec 10, 2024 09:00AM
Dec 3, 2024 09:00AM
Jul 17, 2024 09:00AM Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Mar 21, 2024 04:05PM
Nov 16, 2023 01:34PM
Nov 16, 2023 08:00AM
Nov 16, 2023 12:00AM
Nov 9, 2023 04:05PM
May 11, 2023 04:05PM
Apr 20, 2023 06:01AM Dermata Therapeutics (DRMA) Receives Type C Meeting Response from the FDA, Submits DMT310 End of Phase 2 Meeting Package
Apr 20, 2023 06:00AM
Nov 15, 2021 04:01PM

322,940 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All